Advisors Preferred’s Genmab GMAB Stock Holding History

Advisors Preferred’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,720	Closed	-$1.36M	–	261
2026 Q1	$1.36M	Buy	+50,720	New	+$1.52M	0.2%	100
2025 Q2	–	Sell	-4,481	Closed	-$83.6K	–	236
2025 Q1	$83.6K	Buy	+4,481	New	+$94K	0.01%	218
2024 Q1	–	Sell	-2,563	Closed	-$82.3K	–	216
2023 Q4	$82.3K	Buy	+2,563	New	+$80.5K	0.01%	160

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Advisors Preferred's GMAB Position: Q2 2026 in Review

Advisors Preferred sold out of Genmab (GMAB) in Q2 2026, closing a stake of 50,720 shares — an estimated $1.36M sold.

Advisors Preferred first reported a position in GMAB in Q4 2023 and held it in 3 quarters. The position peaked at $1.36M in Q1 2026. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Advisors Preferred reported no remaining Genmab position as of Q2 2026 after selling out during the quarter.
Advisors Preferred sold 50,720 Genmab shares in Q2 2026, an estimated $1.36M.
Advisors Preferred first reported a position in Genmab in Q4 2023 and held it in 3 quarters.
Advisors Preferred's Genmab position peaked at $1.36M in Q1 2026.
289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Advisors Preferred's 13F filing for Q2 2026, filed 11 Aug 2026.